TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.
Bioxcel Therapeutics has made a disclosure in their Current Report on Form 8-K, which includes information under Item 7.01 and is incorporated in Item 8.01, excluding the sixth paragraph.
The most recent analyst rating on (BTAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
Average Trading Volume: 9,722,388
Technical Sentiment Signal: Sell
Current Market Cap: $45.27M
For detailed information about BTAI stock, go to TipRanks’ Stock Analysis page.